by GlyTherix | Aug 11, 2022
We are pleased to announce that our key composition of matter patent for GlyTherix Ltd’s proprietary antibody to GPC-1 is now registered in 20 countries including US, Australia, China and Japan as well as several key European countries. The company’s IP estate is...
